Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …

An in vitro pharmacokinetic model mimicking human serum drug concentrations, based on a
dialyzer unit, was developed to study the efficacies of continuous infusion and intermittent …

The pharmacodynamics and pharmacokinetics of ceftazidime administered by continuous
infusion and intermittent bolus over a 4-day period were compared. We conducted a …

Since beta-lactam antibiotics have concentration-independent killing, bacterial eradication is
a function of the time the serum drug concentration remains above the drug's MIC (T> MIC) …

We compared the pharmacodynamics and killing activity of ceftazidime, administered by
continuous infusion and intermittent bolus, against Pseudomonas aeruginosa ATCC 27853 …

Ceftazidime is frequently used in critically ill patients, particularly for the treatment of
Pseudomonas aeruginosa infections. The recommended dosing regimen is based on …

Altered pharmacokinetics (PK) of hydrophilic antibiotics in critically ill patients is common,
with possible consequences for efficacy and resistance. We aimed to describe ceftazidime …

The combination of ceftazidime and avibactam possesses potent activity against resistant
Gram-negative pathogens, including Pseudomonas aeruginosa. We compared the …

Objective: This study aimed too compare the pharmacokinetic and pharmacodynamic profile
of intermittent and continuously infused ceftazidime in patients with nosocomial pneumonia …

Cefepime, a fourth-generation cephalosporin, is currently one of the primary agents used in
combination with an aminoglycoside when treating Pseudomonas aeruginosa infections …